In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Imunon (IMNN – Research Report), with a price target of $12.00. The company’s shares closed yesterday at $1.21.
Bodnar covers the Healthcare sector, focusing on stocks such as Agenus, Nkarta, and Gracell Biotechnologies. According to TipRanks, Bodnar has an average return of -9.0% and a 32.74% success rate on recommended stocks.
Imunon has an analyst consensus of Moderate Buy, with a price target consensus of $12.00.
See today’s best-performing stocks on TipRanks >>
IMNN market cap is currently $11.01M and has a P/E ratio of -0.29.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Celsion Corp . engages in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.
Read More on IMNN:
- Imunon announces data on PlaCCine vaccines
- Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON’s PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv
- IMUNON to Hold Second Quarter 2023 Financial Results and Business Update Conference Call on Thursday, August 10, 2023
- IMUNON Unveils New Manufacturing Capabilities at Huntsville’s HudsonAlpha Biotech Campus
- Imunon unveils new clinical materials production facility at HudsonAlpha
